PharmaFocus Today – Page 136 – media

11.4 billion, Boston Science has a big move

On February 21, 2025, Boston Scientific (NYSE: BSX) announced that its fully funded subsidiary, American Medical Systems Europe B.V. (“AMS Europe”), has priced a total of 1.5 billion euros (approximately RMB 11.377 billion) in notes (a type of bond issuance). The funds obtained from this issuance, along with the company’s cash on hand, will be used for debt repayment, working capital, and potential future acquisitions. As of February 21st, Boston Scientific’s latest stock price is $104.49 per share, with a total market value of $154 billion, reaching its highest point since going public. 01. Issuing bonds worth billions, PFA’s performance skyrocketed by 172% The notes issued this time consist of two transactions, one with a total principal of 850 million euros and an interest rate of 3.000%, due in 2031; The other principal amount is 650 million euros, with an interest rate of 3.250%, due in 2034. The bill will ...
- Source: drugdu
- 324
- February 26, 2025
9 Medical Devices Enter Innovation Channel

Recently, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 2 of 2025), intending to approve 9 medical devices to enter the innovation channel. 1. Peripheral arterial stent graft system: Jiangsu Pupeng Medical Technology Co., Ltd Pupeng Medical was established on December 16, 2019, and is a subsidiary of Jiangsu Zhenyi Medical Technology Co., Ltd. (hereinafter referred to as Zhenyi Medical). It is reported that Zhenyi Medical focuses on the cardiovascular disease field with extremely high mortality and disability rates, and the domestic market is still blank. Its business comprehensively covers multiple interventional treatment fields such as heart valves, peripheral and coronary arteries. It is the first platform enterprise to achieve one-stop innovative solutions for blood flow management on a global scale. In addition to the products that entered the innovation channel this time, Park Peng Medical also ...
- Source: drugdu
- 397
- February 26, 2025
HPV vaccine market is about to expand, and the Bio-Vaccine ETF (562860) rose 1.14% during the session

As of 10:13 on February 20, 2025, the CSI Vaccine and Biotechnology Index rose strongly by 1.13%, with constituent stocks Yifang Biotech rising by 7.45%, Dizhe Pharmaceuticals rising by 6.93%, Shuanglu Pharmaceuticals rising by 4.37%, and Wanze Shares, Dongbao Bio and other stocks following suit. Bio-Vaccine ETF (562860) rose by 1.14%, and the intraday turnover has reached 6.5605 million yuan. In terms of scale, the scale of Bio-Vaccine ETF has increased by 3.2427 million yuan in the past week, achieving significant growth. It is worth noting that the valuation of the CSI Vaccine and Biotechnology Index tracked by the fund is at a historical low, with the latest price-to-book ratio PB being 2.95 times, which is lower than the index’s 83.43% of the past five years, and the valuation cost-effectiveness is outstanding. Data shows that as of January 27, 2025, the top ten weighted stocks in the CSI Vaccine and ...
- Source: drugdu
- 340
- February 24, 2025
Over 1.2 billion US dollars! CSPC Pharmaceuticals ROR1 ADC reaches international licensing cooperation

On February 19, CSPC Pharmaceutical Group announced that its subsidiary CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Bio”) has reached an important agreement with Radiance Biopharma. According to the agreement, Radiance Biopharma will obtain the exclusive development and commercialization rights of Jushi Bio’s independently developed SYS6005 project in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia and Canada. Jushi Bio will receive a down payment of US$15 million, a development and regulatory milestone amount of US$150 million, a sales milestone amount of US$1.075 billion, and a certain percentage of sales revenue. SYS6005: An innovative ADC drug SYS6005 is a monoclonal antibody-drug conjugate (ADC) independently developed by Jushi Bio. It can bind to specific receptors on the surface of tumors, enter cells through endocytosis and release toxins to kill tumor cells. SYS6005 uses Jushi Bio’s ...
- Source: drugdu
- 309
- February 24, 2025
Hengrui Medicine enters the children’s myopia track, this “myopia magic drug” is about to debut

Recently, Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, submitted a marketing authorization application for HR19034 Eye Drops (Atropine Sulfate Eye Drops) to the National Medical Products Administration, which has been accepted. This product is mainly used to prevent and control the progression of myopia in children and adolescents. According to the Yaozhi Data global drug analysis system, Hengrui Medicine’s HR19034 project started clinical trials in April 2021. After completing the Phase I trial, the company immediately started Phase II/Phase III research. According to Hengrui’s announcement, the project will complete a three-year clinical trial in August 2024. Research data showed that HR19034 was superior to the control group in terms of the primary endpoint and demonstrated good safety and tolerability in children with myopia. The most common application of atropine in ophthalmology is mydriasis. Atropine sulfate at a concentration of 1% is usually used for fundus examination and eye examination ...
- Source: drugdu
- 375
- February 24, 2025
Pfizer’s pan-KRAS inhibitor cancer drug approved for clinical trials

On February 17, the CDE official website announced that Pfizer’s Class 1 new drug “PF-07934040 Tablets” has obtained implicit approval for clinical trials and is intended to be developed to treat advanced solid tumors carrying KRAS mutations. PF-07934040 is a pan-KRAS inhibitor under development and is currently undergoing Phase 1 clinical trials internationally. According to Yaozhi data, this is the first time that the product has been approved for IND in China. According to Pfizer’s official website, PF-07934040 is a pan-KRAS “ON/OFF” inhibitor that has activity against wild-type (wt) KRAS and major mutant subtypes, and is inactive against NRAS or HRAS. PF-07934040 has been shown to bind to both the OFF (GDP-bound) and ON (GTP-loaded) states of KRAS wt, and has very low binding affinity to mutants, with a selectivity for binding to KRAS that is 5,000 times higher than HRAS/NRAS. https://news.yaozh.com/archive/45010.html
- Source: drugdu
- 477
- February 24, 2025
First Pharmaceutical plans to increase the guarantee limit for its loss making subsidiary

Recently, the “time-honored” pharmaceutical distribution enterprise in Shanghai, First Pharmaceutical (600833. SH), announced the expected guarantee amount for its wholly-owned subsidiary in 2025. To support the operation and development of its wholly-owned subsidiaries, First Pharma plans to provide an additional guarantee limit of no more than RMB 210 million for three wholly-owned subsidiaries: First Pharma (Hong Kong) Limited (hereinafter referred to as “First Pharma Hong Kong”), Shanghai HSBC Pharmaceutical Materials Co., Ltd. (hereinafter referred to as “HSBC Pharma”), and Shanghai First Pharmaceutical Store Chain Operation Co., Ltd. (hereinafter referred to as “First Pharma Chain”). The above matters will be submitted to the shareholders’ meeting for deliberation on February 27, 2025. According to the arrangement, the newly added guarantee amounts for Yiyi Hong Kong, HSBC Pharmaceuticals, and Yiyi Chain are 60 million yuan, 100 million yuan, and 50 million yuan respectively, accounting for 20.97% of the latest net assets of ...
- Source: drugdu
- 249
- February 22, 2025
supports the introduction of original drugs for domestic production; National Healthcare Security Administration

NO.1 National Medical Products Administration: Support the introduction of original drugs for domestic production On February 20, according to the WeChat official account of the State Food and Drug Administration, Huang Guo, the deputy director of the State Food and Drug Administration, recently led a team to Shandong for research. Huang Guo emphasized that the National Medical Products Administration attaches great importance to the research and development of innovative drugs and external cooperation. The drug regulatory authorities will further optimize the review and approval process, support the introduction of original drugs for domestic production, and enhance the confidence of multinational enterprises in investing and developing in China; At the same time, relevant policies will be continuously improved to support and guide domestic enterprises, research and development institutions, etc. to increase the research and development of innovative drugs and high-quality generic drugs, and actively participate in competition in both domestic and ...
- Source: drugdu
- 257
- February 22, 2025
Two innovative medical devices have recently been approved

Recently, the National Medical Products Administration approved registration applications for two innovative medical devices, namely: the percutaneous glomerular filtration rate measurement device from Meidekang Company (hereinafter referred to as Meidekang) and the disposable balloon cryoablation catheter from Xinuopu Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as Xinuopu Medical). Meidekang: Combination of medicine and equipment to meet clinical needs MediBeacon was founded in 2012 and is dedicated to the research and development of medical optical diagnostic products, mainly involving fluorescent contrast agents and corresponding equipment. In 2019, East China Pharmaceutical invested 30 million dollars in Medecin, and obtained the exclusive commercialization rights of all Medecin products (including the follow-up development of new products) in 25 Asian countries or regions, including Chinese Mainland, Hong Kong, Taiwan, Singapore, and Malaysia, so as to layout the field of renal function monitoring. The approved percutaneous glomerular filtration rate measurement device – MediBeacon ® The ...
- Source: drugdu
- 212
- February 22, 2025
Urban cultural tourism and industrial development are gradually achieving two-way empowerment

Recently, the 9th Asian Winter Games came to a successful conclusion in Harbin, Heilongjiang Province. Ice and snow events have promoted the further popularization of ice and snow sports, and promoted the host city to continue and enhance the “Erbin” popularity of the previous ice and snow season. “Erbin” not only attracted domestic and foreign tourists to the ice and snow appointment, but also promoted the development of local enterprises. Harbin Pharmaceutical Group, a listed company, is one of the beneficiaries. Hu Xiaoping, secretary of the Party Committee of Harbin Pharmaceutical Group and chairman of Harbin Pharmaceutical Group, said in an interview with a reporter from Shanghai Securities News recently that the city’s attention and recognition have increased, talents have flocked in, and corporate development has benefited accordingly. “The city is popular, and the company will naturally benefit” Harbin Pharmaceutical Group is the first listed company in the pharmaceutical industry ...
- Source: drugdu
- 378
- February 22, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.